HMGCR and neoplasm: By identifying the E2F1–HMGCR axis as a key driver of this resistance, we demonstrate that HMGCR inhibition restores ferroptosis sensitivity, rendering immune-refractory tumor cells susceptible to ACT and PD-1 blockade.